CXC Chemokine Receptor 2 Antibodies
The human CXCR2 is the prototypic neutrophil chemotactic receptor. It can be activated by a variety of ligands including CXCL1, CXCL2, CXCL6 and CXCL8. Several small molecule CXCR2 antagonists including SB 656933 have been discovered. CXCR2-dependent migration requires activation of many proteins that may form a “chemosynapse” with the receptors. Agonists at high concentrations induce phosphorylation of CXCR2, leading to homologous desensitization, receptor internalization, and partial degradation. CXCR2 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal threonine347 (pT347-CXCR2), serine351/serine352 (pS351/pS352-CXCR2) and serine353/threonine355 (pS353/pT356-CXCR2). This nomenclature refers to the human CXCR2 but is highly conserved in mice and rats. For more information on CXCR2 pharmacology please refer to the IUPHAR database. For further reading refer to:
Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.